Fig. 2: ctDNA positivity before, during, and after neoadjuvant therapy across receptor subtypes.
From: Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors
A Bar plots showing the proportion of patients by the ctDNA status (ctDNA-positive versus ctDNA-negative) at pretreatment (T0), 3 weeks after initiation of paclitaxel treatment with or without an investigational drug (T1), at 12 weeks post-paclitaxel treatment before the anthracycline (AC) regimen (T2), and post-NAT before surgery (T3) in hormone receptor-positive/HER2-negative (HR + HER2-), triple-negative breast cancer (TNBC), and HER2-positive (HER2 + ) breast cancer subtypes. The p-values were calculated using Chi-squared tests. B Line plot showing the proportion of ctDNA-positive patients from T0 to T3, stratified by receptor subtype.
